Showing results (71-80 of 181) with videos related to

Sort By:
Pageof 19
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 2015
Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimensTilmann Bochtler, Ute Hegenbart, Christina Kunz, et al.
Cytometry. Part B, Clinical Cytometry|December 16, 2015
Potential therapeutic targets in plasma cell disorders: A flow cytometry studyKatharina Lisenko, Stefan Schönland, Ute Hegenbart, et al.
Plos Genetics|October 28, 2024
STIL overexpression shortens lifespan and reduces tumor formation in miceAmira-Talaat Moussa, Marco R Cosenza, Timothy Wohlfromm, et al.
Human Genetics|July 24, 2002
Study of 30 patients with unexplained developmental delay and dysmorphic features or congenital abnormalities using conventional cytogenetics and multiplex FISH telomere (M-TEL) integrity assaySusanne Popp, Birgit Schulze, Martin Granzow, et al.
European Journal of Pediatrics|July 12, 2002
TSC1 and TSC2 mutations in tuberous sclerosis, the associated phenotypes and a model to explain observed TSC1/ TSC2 frequency ratiosNicola Langkau, Nicola Martin, Regine Brandt, et al.
Genes, Chromosomes & Cancer|January 15, 2010
NPM1 is overexpressed in hyperdiploid multiple myeloma due to a gain of chromosome 5 but is not delocalized to the cytoplasmNiels Weinhold, Jerome Moreaux, Marc S Raab, et al.
International Journal of Cancer|December 13, 2002
Hodgkin's lymphoma cell lines are characterized by frequent aberrations on chromosomes 2p and 9p including REL and JAK2Stefan Joos, Martin Granzow, Heidi Holtgreve-Grez, et al.
Plos One|March 15, 2014
Sequencing of a patient with balanced chromosome abnormalities and neurodevelopmental disease identifies disruption of multiple high risk loci by structural variationJonathon Blake, Andrew Riddell, Susanne Theiss, et al.
Leukemia & Lymphoma|April 30, 2013
Next-generation sequencing of cancer consensus genes in lymphomaJennifer Hüllein, Alexander Jethwa, Tatjana Stolz, et al.
Frontiers in Immunology|August 7, 2018
CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma-Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront ResistanceAnja Seckinger, Jens Hillengass, Martina Emde, et al.
Pageof 19